Yunyan Li

Yunyan Li

Auto-generated profile, based on publicly available information

Yunyan Li

Skin Disease Research Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
YLYunyan Li
Yunyan Li
ZCZiyang Cui
Ziyang Cui
XSXiaole Song
Xiaole Song
YCYeqing Chen
Yeqing Chen
CLCang Li
Cang Li
RCRutao Cui
Rutao Cui
Purpose: To identify the specific intratumoral and microenvironmental heterogeneity of acral melanoma (AM) and mucosal melanoma (MM), we aimed to delineate their distinct cellular compositions, evolutionary trajectories, and subtype-specific therapeutic strategies. Experimental Design: Single-cell transcriptomic and genomic landscapes were analyzed across 42 melanoma (28 AM, 11 MM, and 3 nonacral cutaneous melanoma) samples, supplemented by in vitro and in vivo validation. Tumor and stromal cells were profiled using single-cell RNA sequencing, whole-exome sequencing, and functional assays, including transwell migration, co-culture systems, and xenograft models. Results: Tumor cells exhibited divergent evolutionary routes, with MM dominated by MGP+/PCOLCE+ subpopulations showing high epithelial-to-mesenchymal transition potential. MM displayed elevated neutrophil infiltration and CXCL3+ tumor-associated macrophages, whereas AM was enriched with PI16+ cancer-associated fibroblasts promoting tumor proliferation. Molecular classification revealed MM subtypes: an antigen-presenting subtype linked to favorable outcomes and a proliferative subtype associated with recurrence. TIGIT+ regulatory T cells were enriched in AM, suggesting targeted inhibition potential. Genomic analysis connected BRAF/NRAS mutations to ALDOA+ stem-like tumor cells and identified prostaglandin D2 synthetase as a therapeutic target in triple–wild-type/melanomas. Conclusions: Our study provides a comprehensive comparison of AM and MM, uncovering subtype-specific stromal–immune interactions and molecular programs. The findings highlight actionable targets (e.g., TIGIT in AM and CXCL3+ macrophages in MM) and propose a framework for precision therapies, biomarker-driven trials, and risk stratification to improve outcomes in these aggressive melanomas.

13 June 2025
Verified
Other
Open access
YLYunyan Li
Yunyan Li
ZCZiyang Cui
Ziyang Cui
XSXiaole Song
Xiaole Song
YCYeqing Chen
Yeqing Chen
CLCang Li
Cang Li
RCRutao Cui
Rutao Cui
Table S2 from Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas

13 June 2025
Verified
Other
Open access
YLYunyan Li
Yunyan Li
ZCZiyang Cui
Ziyang Cui
XSXiaole Song
Xiaole Song
YCYeqing Chen
Yeqing Chen
CLCang Li
Cang Li
RCRutao Cui
Rutao Cui
Table S1 from Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas

13 June 2025
Verified
Other
Open access
YLYunyan Li
Yunyan Li
ZCZiyang Cui
Ziyang Cui
XSXiaole Song
Xiaole Song
YCYeqing Chen
Yeqing Chen
CLCang Li
Cang Li
RCRutao Cui
Rutao Cui
Table S4 from Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas

13 June 2025
Verified
Other
Open access
YLYunyan Li
Yunyan Li
ZCZiyang Cui
Ziyang Cui
XSXiaole Song
Xiaole Song
YCYeqing Chen
Yeqing Chen
CLCang Li
Cang Li
RCRutao Cui
Rutao Cui
Table S6 from Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas